<DOC>
	<DOCNO>NCT01204853</DOCNO>
	<brief_summary>The safety efficacy 100 mg daily oral dose sitaxentan sodium demonstrate STRIDE clinical trial program . Sitaxentan sodium approve EU , Canada Australia . In study , safety efficacy administration sitaxentan sodium dose 100 mg alone combination another medication investigate Japanese PAH patient .</brief_summary>
	<brief_title>A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>Has current diagnosis symptomatic PAH Has 6MWT distance 150 450 meter distance Previous exposure endothelin receptor antagonist Has uncontrolled systemic hypertension evidence sit systolic blood pressure &gt; 160 mm Hg sit diastolic blood pressure &gt; 100 mm Hg Screening . Has hypotension define systolic arterial pressure &lt; 90 mm Hg sit 5 minute Screening .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>sitaxentan sodium hypertension</keyword>
</DOC>